Bariatric surgery leads to long-term remission and reduced incidence of diabetes, hypertension, and dyslipidemia. Short-term studies suggest reduction in specific fat depots may be more predictive of health improvement than reduced body mass index (BMI). Visceral, subcutaneous, epicardial, and liver fat, measured 11 years after bariatric surgery, were associated with long-term remission and incidence of diabetes, dyslipidemia, and hypertension.
Methods:
Fat depots an average of 11 (maximum 14) years after surgery were quantified by noncontrast computed tomography in subjects who did (N = 261; 86% gastric bypass) or did not (N = 243) have bariatric surgery. Multiple regression related fat depots to disease endpoints with and without adjustment for change in BMI and surgical status.
Results:
Visceral fat was 42% lower, subcutaneous fat 20% lower, epicardial fat 30% lower, and liver-to-spleen density ratio 9% higher at follow-up in the bariatric surgery group compared with the nonsurgery group (all P < 0.01). Higher visceral fat at follow-up exam was significantly associated with reduced remission and increased incidence of diabetes, hypertension, and dyslipidemia. Subcutaneous fat was not associated with disease. The liver-to-spleen ratio was associated with the remission and incidence of hypertriglyceridemia and not with other fat depots. Epicardial fat was related to incidence of elevated low-density lipoprotein cholesterol and low high-density lipoprotein cholesterol.
Conclusions:
Whether or not a patient shows greater long-term diabetes, dyslipidemia, or hypertension remission or incidence after bariatric surgery appears dependent on the amount of fat within specific fat depots measured at follow-up. Furthermore, associations of the three disease endpoints with different fat depots suggest varied fat depot pathology.
Get full access to this article
View all access options for this article.
References
1.
FlegalKM, GraubardBI, WilliamsonDF, et al.Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA, 2007; 298:2028–2037.
2.
BrittonKA, MassaroJM, MurabitoJM, et al.Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. J Am Coll Cardiol, 2013; 62:921–925.
3.
NeelandIJ, TurerAT, AyersCR, et al.Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA, 2012; 308:1150–1159.
4.
SahakyanKR, SomersVK, Rodriguez-EscuderoJP, et al.Normal-weight central obesity: Implications for total and cardiovascular mortality. Ann Intern Med, 2015; 163:827–835.
5.
PouKM, MassaroJM, HoffmannU, et al.Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: The Framingham Heart Study. Circulation, 2007; 116:1234–1241.
6.
LimS, MeigsJB. Links between ectopic fat and vascular disease in humans. Arterioscler Thromb Vasc Biol, 2014; 34:1820–1826.
7.
MarchesiniG, BugianesiE, ForlaniG, et al.Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology, 2003; 37:917–923.
8.
Yki-JarvinenH. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol, 2014; 2:901–910.
9.
FabbriniE, MagkosF, MohammedBS, et al.Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A, 2009; 106:15430–15435.
10.
DespresJP, NadeauA, TremblayA, et al.Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes, 1989; 38:304–309.
11.
IacobellisG, SinghN, WhartonS, et al.Substantial changes in epicardial fat thickness after weight loss in severely obese subjects. Obesity (Silver Spring), 2008; 16:1693–1697.
12.
MikhalkovaD, HolmanSR, JiangH, et al.Bariatric surgery-induced cardiac and lipidomic changes in obesity-related heart failure with preserved ejection fraction. Obesity (Silver Spring), 2018; 26:284–290.
13.
SjostromL, LindroosAK, PeltonenM, et al.Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med, 2004; 351:2683–2693.
14.
SjostromL, NarbroK, SjostromCD, et al.Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med, 2007; 357:741–752.
15.
AdamsTD, GressRE, SmithSC, et al.Long-term mortality after gastric bypass surgery. N Engl J Med, 2007; 357:753–761.
16.
AdamsTD, DavidsonLE, LitwinSE, et al.Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med, 2017; 377:1143–1155.
17.
SchauerPR, BhattDL, KirwanJP, et al.Bariatric surgery versus intensive medical therapy for diabetes—5-Year outcomes. N Engl J Med, 2017; 376:641–651.
18.
SundstromJ, BruzeG, OttossonJ, et al.Weight loss and heart failure: A Nationwide Study of Gastric Bypass Surgery Versus Intensive Lifestyle Treatment. Circulation, 2017; 135:1577–1585.
19.
FisherDP, JohnsonE, HaneuseS, et al.Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity. JAMA, 2018; 320:1570–1582.
20.
BusettoL, TregnaghiA, BussolottoM, et al.Visceral fat loss evaluated by total body magnetic resonance imaging in obese women operated with laparascopic adjustable silicone gastric banding. Int J Obes Relat Metab Disord, 2000; 24:60–69.
21.
JohanssonL, RoosM, KullbergJ, et al.Lipid mobilization following Roux-en-Y gastric bypass examined by magnetic resonance imaging and spectroscopy. Obes Surg, 2008; 18:1297–1304.
22.
PontiroliAE, FrigeF, PaganelliM, et al.In morbid obesity, metabolic abnormalities and adhesion molecules correlate with visceral fat, not with subcutaneous fat: Effect of weight loss through surgery. Obes Surg, 2009; 19:745–750.
23.
CarrollJF, FranksSF, SmithAB, et al.Visceral adipose tissue loss and insulin resistance 6 months after laparoscopic gastric banding surgery: A preliminary study. Obes Surg, 2009; 19:47–55.
24.
MillerGD, CarrJJ, FernandezAZ. Regional fat changes following weight reduction from laparoscopic Roux-en-Y gastric bypass surgery. Diabetes Obes Metab, 2011; 13:189–192.
25.
UmemuraA, SasakiA, NittaH, et al.Effects of changes in adipocyte hormones and visceral adipose tissue and the reduction of obesity-related comorbidities after laparoscopic sleeve gastrectomy in Japanese patients with severe obesity. Endocr J, 2014; 61:381–391.
26.
BazzocchiA, PontiF, CarianiS, et al.Visceral fat and body composition changes in a female population after RYGBP: A two-year follow-up by DXA. Obes Surg, 2015; 25:443–451.
27.
GalanakisCG, DaskalakisM, ManiosA, et al.Computed tomography-based assessment of abdominal adiposity changes and their impact on metabolic alterations following bariatric surgery. World J Surg, 2015; 39:417–423.
28.
Toro-RamosT, GoodpasterBH, JanumalaI, et al.Continued loss in visceral and intermuscular adipose tissue in weight-stable women following bariatric surgery. Obesity (Silver Spring), 2015; 23:62–69.
29.
AuclairA, MartinJ, BastienM, et al.Is there a role for visceral adiposity in inducing type 2 diabetes remission in severely obese patients following biliopancreatic diversion with duodenal switch surgery?. Obes Surg, 2016; 26:1717–1727.
30.
AdamsTD, PendletonRC, StrongMB, et al.Health outcomes of gastric bypass patients compared to nonsurgical, nonintervened severely obese. Obesity (Silver Spring), 2010; 18:121–130.
31.
RositoGA, MassaroJM, HoffmannU, et al.Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: The Framingham Heart Study. Circulation, 2008; 117:605–613.
32.
ZebI, LiD, NasirK, et al.Computed tomography scans in the evaluation of fatty liver disease in a population based study: The multi-ethnic study of atherosclerosis. Acad Radiol, 2012; 19:811–818.
33.
MofradP, ContosMJ, HaqueM, et al.Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology, 2003; 37:1286–1292.
34.
van WervenJR, SchreuderTC, AartsEO, et al.Hepatic steatosis in morbidly obese patients undergoing gastric bypass surgery: Assessment with open-system 1H-MR spectroscopy. AJR Am J Roentgenol, 2011; 196:W736–W742.
35.
AbdennourM, ReggioS, Le NaourG, et al.Association of adipose tissue and liver fibrosis with tissue stiffness in morbid obesity: Links with diabetes and BMI loss after gastric bypass. J Clin Endocrinol Metab, 2014; 99:898–907.
36.
HedderichDM, HasenbergT, HanederS, et al.Effects of bariatric surgery on non-alcoholic fatty liver disease: Magnetic resonance imaging is an effective, non-invasive method to evaluate changes in the liver fat fraction. Obes Surg, 2017; 27:1755–1762.
37.
ThomasEL, ParkinsonJR, FrostGS, et al.The missing risk: MRI and MRS phenotyping of abdominal adiposity and ectopic fat. Obesity (Silver Spring), 2012; 20:76–87.
38.
KoYH, WongTC, HsuYY, et al.The correlation between body fat, visceral fat, and nonalcoholic fatty liver disease. Metab Syndr Relat Disord, 2017; 15:304–311.
39.
CnopM, LandchildMJ, VidalJ, et al.The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: Distinct metabolic effects of two fat compartments. Diabetes, 2002; 51:1005–1015.
40.
NeelandIJ, AyersCR, RohatgiAK, et al.Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity (Silver Spring), 2013; 21:E439–E447.
41.
RossR, AruJ, FreemanJ, et al.Abdominal adiposity and insulin resistance in obese men. Am J Physiol Endocrinol Metab, 2002; 282:E657–E663.
42.
IacobellisG, RibaudoMC, AssaelF, et al.Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: A new indicator of cardiovascular risk. J Clin Endocrinol Metab, 2003; 88:5163–5168.
43.
YerramasuA, DeyD, VenurajuS, et al.Increased volume of epicardial fat is an independent risk factor for accelerated progression of sub-clinical coronary atherosclerosis. Atherosclerosis, 2012; 220:223–230.
44.
NagyE, JermendyAL, MerkelyB, et al.Clinical importance of epicardial adipose tissue. Arch Med Sci, 2017; 13:864–874.
45.
NakazatoR, RajaniR, ChengVY, et al.Weight change modulates epicardial fat burden: A 4-year serial study with non-contrast computed tomography. Atherosclerosis, 2012; 220:139–144.
46.
van SchinkelLD, SledderingMA, LipsMA, et al.Effects of bariatric surgery on pericardial ectopic fat depositions and cardiovascular function. Clin Endocrinol, 2014; 81:689–695.
47.
KokkinosA, AlexiadouK, LiaskosC, et al.Improvement in cardiovascular indices after Roux-en-Y gastric bypass or sleeve gastrectomy for morbid obesity. Obes Surg, 2013; 23:31–38.
48.
AdamsM, MontagueCT, PrinsJB, et al.Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest, 1997; 100:3149–3153.
49.
BorelAL, NazareJA, SmithJ, et al.Visceral, subcutaneous abdominal adiposity and liver fat content distribution in normal glucose tolerance, impaired fasting glucose and/or impaired glucose tolerance. Int J Obes (Lond), 2015; 39:495–501.
50.
VirtueS, Vidal-PuigA. It's not how fat you are, it's what you do with it that counts. PLoS Biol, 2008; 6:e237.
51.
ShulmanGI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med, 2014; 371:2237–2238.
52.
DavidsonLE, KukJL, ChurchTS, et al.Protocol for measurement of liver fat by computed tomography. J Appl Physiol, 2006; 100:864–868.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
